Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Utilizing MRI and sensorimotor measures to phenotype adrenomyeloneuropathy progression.

Award Number: K23NS140493
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 09/05/2026
PERIOD OF PERFORMANCE END DATE: 08/31/2031

Group Awards By:

View Award Description

Utilizing MRI and sensorimotor measures to phenotype adrenomyeloneuropathy progression. - Project Summary Adrenomyeloneuropathy (AMN), the most common form of X-linked adrenoleukodystrophy, is an untreatable disorder with a heterogeneous symptom profile and progression rate. Adult males and females experience significant disability due to long-tract distal axonopathy in the spinal cord. Novel therapies are being developed, but the lack of sensitive outcome measures and biomarkers of progression has limited the success of clinical trials. It was recently shown that quantitative sensorimotor measures can reflect progression in AMN. Despite this, challenges with synthesizing and interpreting meaning across hundreds of data points for these measures has led to trial failure and lack of clarity on how to accurately define change across this rare disease cohort with variable disease course. The overall hypothesis is that phenotypic subtypes and trajectories of disease can be identified in AMN and localized to MRI indices of damage in spinal cord white matter tracts. This hypothesis will be investigated through the following specific aims: Aim 1. Obtain cross-sectional sensorimotor outcome measures to determine AMN phenotypic subtypes, and correlate them with spinal cord DTI, qMT and mFFE indices to define their neuroanatomic substrates. Quantitative sensorimotor measures will be obtained in a total of 80 individuals with AMN to determine the presence of distinct phenotypic subtypes through machine learning cluster analysis. The relationship of phenotypic subtype clusters to MRI abnormalities in the dorsal columns and lateral corticospinal tracts will then be evaluated. Aim 2a. Determine if longitudinal sensorimotor outcome measures and longitudinal spinal cord DTI, qMT, and MFFE indices change over 2 years. Published data shows the feasibility of measuring AMN progression using quantitative sensorimotor assessments. Aim 2a will validate this work in a prospective study and concurrently evaluate if advanced MRI indices change within 2 years, using AI-based tools and high-resolution mFFE sequences to quantify spinal cord white matter microstructural changes. Aim 2b. Use longitudinal sensorimotor outcome measures to determine disease trajectory clusters over 2 years and determine the relationship of these trajectories with changes in spinal cord DTI, qMT and mFFE indices. This aim will evaluate if 2-year trajectory clustering of quantitative sensorimotor assessments can identify fast vs. slow progressor clusters, as indicated in the preliminary data, then determine if the clusters are related to MRI indices of spinal cord pathology. The candidate requires additional training in MRI acquisition and analysis, advanced machine learning, and biostatistics to complete these aims. This project will provide critically needed information on phenotypes and pathological structure-function relationships in AMN. The knowledge gaps addressed may inform disease prognostication and conduct of trials. This approach can also be useful across other leukodystrophies with modest sample size and high-dimensional data acquisition.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $234,360 )
2026	2026	HUGO W. MOSER RESEARCH INSTITUTE AT KENNEDY KRIEGER, INC.	707 N BROADWAY	BALTIMORE	MD	21205	BALTIMORE CITY	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	9/3/2026	NEW	$234,360
														Subtotal = $234,360

Grand Total All Awards = $234,360

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Utilizing MRI and sensorimotor measures to phenotype adrenomyeloneuropathy progression.

Award Number: K23NS140493

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 09/05/2026

PERIOD OF PERFORMANCE END DATE: 08/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer